The FDA Ordered GLP-1 Vision-Loss Warnings For Some Products. Shares of Eli Lilly and Novo Nordisk Were Unfazed.

Source: International Business Times

The updated labeling covers Mounjaro, Zepbound, Ozempic and Wegovy as investors assess whether the rare risk will affect prescriptions and sales. Scott Olson/Getty Images Eli Lilly and Novo Nordisk shares climbed Monday, outpacing the broader health care sector even as U. S.